Biomarkers in Diagnostics & Therapeutics to Consolidate International Discussions on Rising Trends of Companion Diagnostics and Progress in Personalized Medicine
News Dec 17, 2010
The global biomarker market is estimated to be $20.5 billion by 2014. This figure could be underestimated, looking at the potential of biomarkers to influence decision-making in clinical trials for increased productivity and improved drug successes. Their status is further elevated with their promising applications in clinical diagnostics, where targeted therapeutics can be administered using biomarkers as disease signatures and gene markers to identify patient populations. This allows better monitoring of drug efficacies and enables better prediction and aversion of potential side effects when it comes to selecting therapeutic options.
As a result of biomarkers fuelling the up-and-coming trend of pharmacogenomics and pharmacodiagnostics, it certainly looks like we are not too far from entering the hyped era of personalized medicine where therapies will, in the near future be tailored to individuals’ genetics.
Event Protocol’s Biomarkers in Diagnostics & Therapeutics will provide a platform for industry professionals to discuss the values of incorporating biomarkers into pharmaceuticals and diagnostics development, their potential applications in diseases management such as early prediction and detection of medical conditions as well as in facilitating tailored therapeutics that should be safer and more effective for individuals.
Expect to meet a stellar line-up of speakers from international companies such as Qiagen, Abbott Molecular Inc., Merck & Co., Quintiles Transnational, Lundbeck A/S and more.
Enrich yourself with the latest updates on market dynamics presented by Frost & Sullivan, and join other speakers to scrutinize the promises of biomarker research upon integration into new drug discovery and development. Presentations will also highlight the co-development of biomarkers assays development and molecular diagnostics as well as how this strengthens the field of companion diagnostics and catapults healthcare in the direction of personalized medicine.
Join us for an enriching and empowering conference experience with ample networking opportunities with other professionals in the region. Enquire on time-limited Christmas registration deals and advantage discount schemes (for academics, hospitals and government bodies) as well as exclusive team bookings at firstname.lastname@example.org.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE